{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:21:16Z","timestamp":1790187676276,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012517","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000}}],"reference-count":63,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012517.pub2","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T06:48:45Z","timestamp":1584600525000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia"],"prefix":"10.1002","volume":"2020","author":[{"given":"Sze May","family":"Ng","sequence":"first","affiliation":[{"name":"Southport & Ormskirk NHS Trust, Ormskirk District General Hospital; Department of Paediatrics; Wigan Road Ormskirk Lancashire UK L39 2AZ"},{"name":"University of Liverpool; Department of Women and Children's Health; Ormskirk General Hospital Wigan Road Ormskirk Lancashire UK L39 2AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina M","family":"Stepien","sequence":"additional","affiliation":[{"name":"Salford Royal NHS Foundation Trust; Adult Inherited Metabolic Disorders, The Mark Holland Metabolic Unit; Stott Line Salford UK M6 8HD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashma","family":"Krishan","sequence":"additional","affiliation":[{"name":"University of Liverpool, Alder Hey Children's NHS Foundation Trust; Department of Women's and Children's Health; Eaton Road Liverpool Merseyside UK L12 2AP"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,19]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD012517.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1590\/S0004-27302004000500017","article-title":"One-year clinical evaluation of single morning dose prednisolone therapy for 21-hydroxylase deficiency","volume":"48","author":"Caldato","year":"2004","journal-title":"Arquivos Brasileiros de Endocrinologia e Metabologia"},{"issue":"12","key":"10.1002\/14651858.CD012517.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1210\/jc.2008-0519","article-title":"Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy","volume":"93","author":"German","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13633-016-0035-5","article-title":"Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia","volume":"2016","author":"Nebesio","year":"2016","journal-title":"International Journal of Pediatric Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD012517.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/adc.77.3.214","article-title":"Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia","volume":"77","author":"Silva","year":"1997","journal-title":"Archives of Disease in Childhood"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1749-6632.1985.tb14603.x","article-title":"Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia","volume":"458","author":"Winterer","year":"1985","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"10.1002\/14651858.CD012517.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-3476(85)80486-8","article-title":"Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia","volume":"106","author":"Winterer","year":"1985","journal-title":"Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD012517.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.4103\/2230-8210.141358","article-title":"Comparison of different glucocorticoid regimens in the management of classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.","volume":"18","author":"Ajish","year":"2014","journal-title":"Indian Journal of Endocrinology and Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD012517.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2006-2109","article-title":"Reduced final height outcome in congenital adrenal hyperplasia under prednisone: deceleration of growth velocity during puberty","volume":"92","author":"Bonfig","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD012517.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1210\/jcem.86.10.7972","article-title":"Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement therapy satisfactory?","volume":"86","author":"Charmandari","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0010|cit10","unstructured":"ChiCTR-TRC-09000350 A clinical study of antisterone with angiotensin II and calcium ion antagonist in the treatment of hypertension with adrenal hyperplasia www.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-TRC-09000350"},{"issue":"3","key":"10.1002\/14651858.CD012517.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2265.1985.tb03240.x","article-title":"Effects of high-dose and low-dose naloxone on plasma ACTH in patients with ACTH hypersecretion","volume":"22","author":"Deuss","year":"1985","journal-title":"Clinical Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD012517.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1530\/EJE-09-0170","article-title":"Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: A pharmacokinetic study","volume":"161","author":"Johannsson","year":"2009","journal-title":"European Journal of Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD012517.pub2-BIB0013|cit13","first-page":"291","article-title":"Effects of glucocorticoid therapy on growth hormone (HGH), gonadotropin (FSH and LH), and 17 OH progesterone (17OH P) secretion in congenital adrenal hyperplasia (CAH)","volume":"9","author":"Kelch","year":"1975","journal-title":"Pediatric Research"},{"issue":"11","key":"10.1002\/14651858.CD012517.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1210\/jc.2009-0517","article-title":"Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients","volume":"94","author":"Koenen","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD012517.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1530\/EJE-09-0523","article-title":"Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia","volume":"161","author":"Kroese","year":"2009","journal-title":"European Journal of Endocrinology"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0016|cit16","unstructured":"NCT00151710 Effects of pioglitazone in congenital adrenal hyperplasia clinicaltrials.gov\/show\/NCT00151710"},{"issue":"10","key":"10.1002\/14651858.CD012517.pub2-BIB0017|cit17","first-page":"3535","article-title":"A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia","volume":"81","author":"Laue","year":"1996","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD012517.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1137-45","DOI":"10.1210\/jc.2014-3809","article-title":"A Phase 2 study of chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia","volume":"100","author":"Mallappa","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD012517.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0306-4530(03)00145-8","article-title":"Androgenic influences on neural asymmetry: Handedness and language lateralization in individuals with congenital adrenal hyperplasia","volume":"29","author":"Mathews","year":"2004","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"10.1002\/14651858.CD012517.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1210\/jcem.85.3.6462","article-title":"Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia","volume":"85","author":"Merke","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD012517.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"45-50","DOI":"10.1111\/j.1365-2265.2006.02544.x","article-title":"Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia","volume":"65","author":"Merza","year":"2006","journal-title":"Clinical Endocrinology"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0022|cit22","unstructured":"NCT00001521 Three drug combination therapy versus conventional treatment of children with congenital adrenal hyperplasia clinicaltrials.gov\/show\/NCT00001521"},{"issue":"1","key":"10.1002\/14651858.CD012517.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen.13447","article-title":"Absorption and tolerability of taste-masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency","volume":"88","author":"Neumann","year":"2018","journal-title":"Clinical Endocrinology"},{"issue":"7","key":"10.1002\/14651858.CD012517.pub2-BIB0024|cit24","first-page":"634","article-title":"Adrenocorticotropin stimulation test in congenital adrenal hyperplasia: comparison between standard and low dose test","volume":"86","author":"Panamonta","year":"2003","journal-title":"Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0025|cit25","unstructured":"EUCTR2015-003996-32-FR Multicentric evaluation of in utero dexamethasone (DEX) on the cognitive development of children at risk of congenital adrenal hyperplasia - PRENATAL DEX Study www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-003996-32-FR"},{"issue":"4","key":"10.1002\/14651858.CD012517.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/jcph.424","article-title":"Comparison of cortisol exposures and pharmacodynamic adrenal steroid responses to hydrocortisone suspension vs. commercial tablets","volume":"55","author":"Sarafoglou","year":"2015","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012517.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1210\/jcem-70-3-642","article-title":"Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia","volume":"70","author":"Spritzer","year":"1990","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD012517.pub2-BIB0028|cit28","article-title":"A pharmacokinetic and biomarker study of the corticotropin-releasing factor receptor antagonist nbi-77860 in adult females with classic, 21-hydroxylase deficiency, congenital adrenal hyperplasia (CAH)","volume":"36","author":"Auchus","year":"2015","journal-title":"Endocrine Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012517.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2015-3574","article-title":"Single-dose study of a corticotropin-releasing factor receptor-1 antagonist in women with 21-hydroxylase deficiency","volume":"101","author":"Turcu","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD012517.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2265.2009.03636.x","article-title":"A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort TM) versus conventional hydrocortisone (Cortef TM) in the treatment of congenital adrenal hyperplasia","volume":"72","author":"Verma","year":"2010","journal-title":"Clinical Endocrinology"},{"issue":"8","key":"10.1002\/14651858.CD012517.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1210\/jc.2003-032051","article-title":"Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise","volume":"89","author":"Weise","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.ijcard.2011.08.534","article-title":"Hypertension with adrenal hyperplasia of the different treatments","volume":"152","author":"Zhang","year":"2011","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"P123","DOI":"10.1186\/1687-9856-2013-S1-P123","article-title":"A pilot study on the effect of three hydrocortisone dosing regimen on 17 hydroxyprogesterone levels in patients with congenital adrenal hyperplasia","volume":"Suppl 1","author":"Salud","year":"2013","journal-title":"International Journal of Pediatric Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD012517.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF02751885","article-title":"Morning steroid profile in children with congenital adrenal hyperplasia under different hydrocortisone schedules","volume":"61","author":"Silva","year":"1994","journal-title":"Indian Journal of Pediatrics"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0035|cit35","unstructured":"NCT03760835 Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment (CareOnTIME) clinicaltrials.gov\/show\/nct03760835"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0036|cit36","unstructured":"NCT02552251 COrticosteroid in congenital adrenal hyperplasia (COCA) clinicaltrials.gov\/show\/NCT02552251"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0037|cit37","unstructured":"EUCTR2011-005822-23-NO A trial comparing continuous subcutaneous hydrocortisone therapy with conventional oral glucocorticoid therapy in congenital adrenal hyperplasia www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-005822-23-NO"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0038|cit38","unstructured":"NCT01771328 Continuous subcutaneous hydrocortisone infusion in congenital adrenal hyperplasia clinicaltrials.gov\/show\/nct01771328"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0039|cit39","unstructured":"EUCTR2015-000711-40-NL Chronocort\u00ae, a slow release medicinal preparation of hydrocortisone, will be compared with currently used glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia seeking to assess its safety, tolerability and effectiveness www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-000711-40-NL"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0040|cit40","unstructured":"NCT02716818 Comparison of chronocort\u00ae with standard glucocorticoid therapy in patients with congenital adrenal hyperplasia clinicaltrials.gov\/show\/NCT02716818"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0041|cit41","unstructured":"EUCTR2012-001104-37-GB Pulses study www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2012-001104-37-GB"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0042|cit42","unstructured":"ISRCTN67193733 The Pulses Study http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ISRCTN67193733"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0043|cit43","unstructured":"NCT03532022 Open-label Comparison of Chronocort\u00ae Versus Standard Glucocorticoid Replacement Therapy (RESTORE) clinicaltrials.gov\/show\/nct03532022"},{"issue":"1","key":"10.1002\/14651858.CD012517.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"37-46","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educational and Psychological Measurement"},{"issue":"2","key":"10.1002\/14651858.CD012517.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"221-32","DOI":"10.1016\/j.beem.2008.09.010","article-title":"Novel strategies for hydrocortisone replacement","volume":"23","author":"Debono","year":"2009","journal-title":"Best Practice & Research. Clinical Endocrinology & Metabolism"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0046|cit46","unstructured":"Deeks JJ Higgins JP Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"712549","DOI":"10.1155\/2010\/712549","article-title":"Duration of suppression of adrenal steroids after glucocorticoid administration","volume":"2010","author":"Fuqua","year":"2010","journal-title":"International Journal of Pediatric Endocrinology"},{"issue":"7414","key":"10.1002\/14651858.CD012517.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0049|cit49","unstructured":"Higgins JP Altman DG Sterne JA on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD012517.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"193-208","DOI":"10.1016\/j.beem.2008.10.010","article-title":"Management of the child with congenital adrenal hyperplasia","volume":"23","author":"Hindmarsh","year":"2009","journal-title":"Best Practice & Research. Clinical Endocrinology & Metabolism"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"g5518","DOI":"10.1136\/bmj.g5518","article-title":"Mimicking the circadian rhythm in glucocorticoid replacement","volume":"349","author":"Hindmarsh","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD012517.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"101-6","DOI":"10.1136\/archdischild-2011-300234","article-title":"Incidence and clinical features of congenital adrenal hyperplasia in Great Britain","volume":"97","author":"Khalid","year":"2012","journal-title":"Archives of Disease in Childhood"},{"issue":"12","key":"10.1002\/14651858.CD012517.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJM200003233421204","article-title":"Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis.","volume":"342","author":"Lai","journal-title":"N Engl J Med."},{"key":"10.1002\/14651858.CD012517.pub2-BIB0054|cit54","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"9","key":"10.1002\/14651858.CD012517.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1210\/jc.2002-020611","article-title":"Consensus statement on 21-hydroxylase deficiency from The Lawson Wilkins Pediatric Endocrine Society and The European Society for Pediatric Endocrinology","volume":"87","author":"Joint LWPES\/ESPE CAH Working Group","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD012517.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.steroids.2013.04.007","article-title":"Diagnosis and management of classical congenital adrenal hyperplasia","volume":"78","author":"Marumudi","year":"2013","journal-title":"Steroids"},{"issue":"4","key":"10.1002\/14651858.CD012517.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000065492","article-title":"Management of congenital adrenal hyperplasia: results of the ESPE questionnaire","volume":"58","author":"Riepe","year":"2002","journal-title":"Hormone Research"},{"issue":"4","key":"10.1002\/14651858.CD012517.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"349-63","DOI":"10.1007\/s11154-007-9053-1","article-title":"Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"8","author":"Riepe","year":"2007","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0059|cit59","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group Chapter 11: Presenting results and \u2018Summary of findings\u2019 tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012517.pub2-BIB0060|cit60","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P et al on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"11","key":"10.1002\/14651858.CD012517.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"Journal of Clinical Endocrinology Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD012517.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"471-7","DOI":"10.1111\/cen.12265","article-title":"Cardiovascular risk factors in children and adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"80","author":"Subbarayan","year":"2014","journal-title":"Clinical Endocrinology"},{"issue":"10","key":"10.1002\/14651858.CD012517.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.","volume":"13","author":"Staa","year":"Oct 2002","journal-title":"Osteoporos Int."}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T07:32:34Z","timestamp":1659598354000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012517.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,3,19]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012517.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,19]]}}}